Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPopulation pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma
European Journal of Cancer, 06/15/09
Thomas F et al. - Study concludes that erlotinib treatment may present criteria justifying dose individualisation but further studies, including more patients, are necessary to define the modalities of this adaptation.
Methods- Study was undertaken to:
- Analyse the impact of several covariates on the pharmacokinetics of erlotinib and its main metabolite (OSI-420) and
- Determine pharmacokinetic/pharmacodynamic (PK/PD) relationships
- Plasma concns of erlotinib and OSI-420 of 42 pts were analysed to evaluate the impact of pts’ covariates on erlotinib PK
- Presence of SNP in ABCB1 (2677G > T/A and 3435C > T), ABCG2 (421C > A) and CYP3A5 (6986G > A) was investigated
- PK/PD relationships between plasma drug exposure (AUC) and early drug response or toxicity were also studied
- Covariates retained to predict erlotinib clearance were ALAT (alanine amino transferase), age and ABCG2 polymorphism
- A significant link between drug exposure and the grade of skin rash was observed
- However, early response to treatment was not correlated to the erlotinib AUC
Related Articles
Basaloid squamous cell carcinomas of the head and neck
Bulletin du Cancer, 10/19/09
Relevance Score: 94%
HER2 expression predicts improved survival in patients with cervical node–positive head and neck squamous cell carcinoma
Otolaryngology Head and Neck Surgery, 10/13/09
Relevance Score: 94%
Distinct population of highly malignant cells in a head and neck squamous cell carcinoma cell line established by xenograft model
BMC: Journal of Biomedical Science, 11/17/09
Relevance Score: 93%
Clinicopathologic risk factors for distant metastases from head and neck squamous cell carcinomas
European Journal of Surgical Oncology, 11/16/09
Relevance Score: 93%
Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009
The Lancet Oncology, 11/02/09
Relevance Score: 93%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial)
Annals of Oncology, 12/04/09
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
Annals of Oncology, 12/04/09
Three-dimensional (3D) Overlay Culture Models of Human Breast Cancer Reveal a Critical Sensitivity to MEK Inhibitors
Journal of Pharmacology and Experimental Therapeutics, 12/04/09
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
Annals of Oncology, 12/04/09
Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients
Scandinavian Journal of Pain, 12/04/09
Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib
Clinical Pharmacology & Therapeutics, 12/03/09
Sponsor
Article Search
Sponsor